|
"teo e k"的相關文件
顯示項目 1-5 / 5 (共1頁)
1
每頁顯示[10|25|50]項目
| 臺大學術典藏 |
2021-09-04T06:12:16Z |
Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy
|
Lui Y.Y.-N.; Tsoi K.K.-F.; Wong V.W.-S.; JIA-HORNG KAO; Hou J.-L.; Teo E.-K.; Mohamed R.; Piratvisuth T.; Han K.-H.; Mihm U.; Wong G.L.-H.; Chan H.L.-Y. |
| 臺大學術典藏 |
2021-01-15T03:46:30Z |
The impact of wire caliber on ERCP outcomes: a multicenter randomized controlled trial of 0.025-inch and 0.035-inch guidewires
|
Bassan M.S.; Sundaralingam P.; Fanning S.B.; Lau J.; Menon J.; Ong E.; Rerknimitr R.; Seo D.-W.; Teo E.K.; HSIU-PO WANG; Reddy D.N.; Goh K.L.; Bourke M.J. |
| 臺大學術典藏 |
2018-09-10T08:16:48Z |
Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy
|
Lui, Y.Y.-N.;Tsoi, K.K.-F.;Wong, V.W.-S.;Kao, J.-H.;Hou, J.-L.;Teo, E.-K.;Mohamed, R.;Piratvisuth, T.;Han, K.-H.;Mihm, U.;Wong, G.L.-H.;Chan, H.L.-Y.; JIA-HORNG KAO |
| 國立成功大學 |
2006-07 |
Safety and antiviral activity of pradefovir in patients with chronic hepatitis B virus infection: 48-week analysis of a phase 2 study
|
Lim, S. G.; Lee, K. S.; Chuang, W. L.; Hwang, S. G.; Cho, M.; Lai, M. Y.; Chao, Y. C.; Chang, Ting-Tsung; Han, K. H.; Lee, C. M.; Um, S. H.; Yeon, J. E.; Yang, S. S.; Teo, E. K.; Peng, C. Y.; Lin, H. H.; Yang, S. S.; Huo, T. I.; Nguyen, T.; Chen, T. Y.; Hu, K. Q.; Xu, Y.; Sullivan-Bolyai, J. Z. |
| 國立成功大學 |
2006-04 |
Safety, tolerability and antiviral activity of pradefovir mesylate in patients with chronic hepatitis B virus infection: 48-week analysis of a phase 2 study
|
Lee, K. S.; Lim, S. G.; Chuang, W. L.; Hwang, S. G.; Cho, M.; Lai, M. Y.; Chao, Y. C.; Chang, Ting-Tsung; Han, K. H.; Lee, C. M.; Um, S. H.; Yeon, J. E.; Yang, S. S.; Teo, E. K.; Peng, C. Y.; Lin, H. H.; Huo, T. I.; T. Nguyen; Chen, T. Y.; Hu, K. Q.; Xu, Y.; J. Z. Sullivan-Bólyai; Lee, K. S. |
顯示項目 1-5 / 5 (共1頁)
1
每頁顯示[10|25|50]項目
|
